Needham & Company LLC Reaffirms “Hold” Rating for Omeros (NASDAQ:OMER)

Needham & Company LLC reissued their hold rating on shares of Omeros (NASDAQ:OMERFree Report) in a research note released on Thursday morning, Benzinga reports.

Separately, StockNews.com upgraded shares of Omeros from a sell rating to a hold rating in a report on Wednesday, April 3rd.

Get Our Latest Analysis on OMER

Omeros Stock Performance

OMER stock opened at $3.45 on Thursday. The stock’s 50 day moving average price is $3.49 and its 200 day moving average price is $3.26. The firm has a market cap of $199.89 million, a P/E ratio of -1.75 and a beta of 1.34. Omeros has a 1 year low of $0.92 and a 1 year high of $7.80.

Omeros (NASDAQ:OMERGet Free Report) last issued its quarterly earnings data on Monday, April 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter. On average, research analysts predict that Omeros will post -1.81 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC boosted its stake in Omeros by 51.2% in the 3rd quarter. Barclays PLC now owns 45,629 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 15,456 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Omeros by 59.3% in the fourth quarter. SG Americas Securities LLC now owns 30,438 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 11,333 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in Omeros by 200.0% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 30,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 20,000 shares during the period. Ancora Advisors LLC increased its position in Omeros by 23.1% during the third quarter. Ancora Advisors LLC now owns 210,023 shares of the biopharmaceutical company’s stock worth $613,000 after purchasing an additional 39,475 shares during the last quarter. Finally, Cerity Partners LLC purchased a new position in Omeros during the fourth quarter worth approximately $71,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

(Get Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Further Reading

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.